TNFRSF1B and neoplasm: Together, the different studies set the basis for the hypothesis that modalities directed to TNFR2 will reduce the presence and activities of TNFR2+ Tregs in tumors, leading to improved anti-tumor activities that may be exerted by lymphocytes, such as cytotoxic T cells (CTLs) [39,40,41,42,43].